Quantitative benefit-risk modelling of infliximab biosimilar inflectra versus reference product remicade in the treatment of Crohn's disease

被引：0

作者：

Catt, Heather ^{[1
]}

Hughes, Dyfrig ^{[2
]}

Bodger, Keith ^{[1
]}

Kirkham, Jamie ^{[1
]}

机构：

[1] Univ Liverpool, Liverpool, Merseyside, England

[2] Univ Bangor, Bangor, Gwynedd, Wales

来源：

TRIALS | 2017年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

P143

引用

页数：2

共 50 条

[21] Benefit-Risk Assessment of the TNF-Antagonists Adalimumab and Certolizumab Pegol for Maintenance Treatment of Crohn's Disease
Colombel, Jean-Frederic
Panaccione, Remo
Robinson, Anne
Thakkar, Roopal
Huang, Bidan
Pollack, Paul F.
GASTROENTEROLOGY, 2011, 140 (05) : S774 - S774
[22] Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management
Johnson, F. Reed
Hauber, A. Brett
Oezdemir, Semra
Siegel, Corey A.
Hass, Steven
Sands, Bruce E.
JOURNAL OF MANAGED CARE PHARMACY, 2010, 16 (08): : 616 - 628
[23] The switch to biosimilar infliximab as a cause of treatment cessation in 3 paediatric patients with Crohn's disease
Vande Velde, S.
ACTA GASTRO-ENTEROLOGICA BELGICA, 2020, 83 (04) : 657 - 659
[24] HACA formation after infliximab (Remicade™) treatment in Crohn's disease is clearly associated with infusion reactions.
Noman, M
Baert, F
D'Haens, G
Van Assche, G
Swijsen, C
Aerden, I
Rutgeerts, P
GASTROENTEROLOGY, 2001, 120 (05) : A621 - A621
[25] Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA's Benefit-Risk Framework to Calculate Net-Benefit Score and Benefit-Risk Ratio
Sun, Stephen
Heske, Suzanne
Mercadel, Melanie
Wimmer, Jean
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (01) : 129 - 137
[26] Efficacy and safety of biosimilar of infliximab (Inflectra) in adult patients with Crohn's disease during 1 year of treatment, followed 6 months of observation: a one-centre retrospective study
Kaniewska, M.
Rydzewska, G.
JOURNAL OF CROHNS & COLITIS, 2016, 10 : S363 - S363
[27] Efficacy and Safety of Biosimilar of Infliximab (Inflectra) in Adult Patients With Crohn Disease During One Year of Treatment Followed 6 Months of Observation - One Center Retrospective Study
Kaniewska, Magdalena A.
Rydzewska, Grazyna
GASTROENTEROLOGY, 2016, 150 (04) : S488 - S489
[28] Improvement in bone mineral density (BMD) of children with Crohn's Disease following treatment with infliximab (remicade): Preliminary observations
Harcke, HT
Kecskemethy, HH
Mehta, D
Proujansky, R
RADIOLOGY, 2001, 221 : 349 - 349
[29] Tracing the historical foundations of infliximab in Crohn's disease treatment: a cited reference analysis
Yeung, Andy Wai Kan
FRONTIERS IN PHARMACOLOGY, 2024, 15
[30] Consistency of treatment benefit with infliximab in patients with moderate-to-severe active Crohn's disease
Vasiliauskas, E
Targan, S
Sands, B
Hanauer, S
Mayer, L
Present, D
Braakman, T
DeWoody, K
Schaible, T
Rutgeerts, P
GASTROENTEROLOGY, 1999, 116 (04) : A837 - A837

← 1 2 3 4 5 →